JPRN-UMIN000027383Not yet recruiting未知
Therapeutic angiogenesis using autologous bone marrow mononuclear cells implantation for Buerger disease - Therapeutic angiogenesis using autologous bone marrow mononuclear cells implantation for Buerger disease
Kyoto Prefectural University School of Medicine0 sites25 target enrollmentStarted: May 18, 2017Last updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 25
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to 80years-old (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1. Even if the disease and the way type are suitable, or informed consent is not obtained from a patient, it is feelings consideration to a patient family. When I am required and it is difficult to be adapted. 2. When diagnosed as malignant tumor by inspections. 3. When it has ischemic cardiopathy and blood circulation reconstruction is not performed. 4. Serious illness diabetic retinopathy with no treatment. 5. When it has serious infection. 6. When critical impaired liver function and renal dysfunction (maintenance dialysis patient removes)exist. 7. When serious anemia which needs blood dyscrasia and transfusion with white corpuscle reduction,critical decrease of platelets, etc. exists. 8. Nursing mother when there are under pregnancy and possibility of pregnancy. 9. Simultaneous with the final examination, or those to the final examination that incorporated and participated in other clinical tests of trial drug or products on the market (medical equipment is included) within 30 days. 10. When the serious anemia which needs blood dyscrasia and transfusion with white corpuscle reduction, a critical decrease of platelets, etc. exists. 11. There are other acute and chronic medical serious and mental state, and abnormalities in a clinical laboratory test result. Danger may increase by test participation. The patient who may have on the interpretation of a test result. The patient to whom the examination responsibility (assignment) doctor judged the participation in the final examination to be unsuitable. 12. In addition, when a family doctor and a medical specialist judge it as a stop.
Investigators
Similar Trials
Completed
Not Applicable
Therapeutic Angiogenesis using Autologous Bone-Marrow Mononuclear Cells ImplantatioCLI(Critical limb ischemia) (ASO, Buerger disease, Collagen disease)JPRN-UMIN000023282Kyoto Prefectural University School of Medicine120
Recruiting
Not Applicable
Therapeutic angiogenesis using bone marro w-derived mononuclear cells implantation for critical limb ischemia (Therapeutic angiogenesis for critical limb ischemia)critical limb ischemia (arteriosclerosis obliterans, Buerger's disease, collagen disease vasculitis)critical limb ischemia, Buerger'a diseaseJPRN-jRCTb050190123Matoba Satoaki50
Suspended
Not Applicable
Therapeutic angiogenesis using bone marrow-derived mononuclear cells implantation for critical limb ischemiawith Buerger's diseasecritical limb ischemia caused by Buerger's diseasecritical limb ischemia, Buerger'a diseaseJPRN-jRCTb050190082Matoba Satoaki25
Completed
Phase 1
Vascular regeneration using autologous mesenchymal stem cells for peripheral arterial diseasePeripheral Arterial Disease (Fontaine stages three and four)JPRN-UMIN000009943Rogenkai Welfare Group5
Completed
Phase 1
A clinical trial to evaluate the effect of bone marrow derived stem cell in diseases Limb IschemiaCTRI/2010/091/000565Department of Biotechnology New Delhi80